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ABSTRACT - Purpose. Parkinson's disease (PD), a common neurodegenerative disorder, is usually treated 
with Levodopa (L-DOPA). The use of this drug, however, is severely limited by the development of side 
effects of the motor system: Levodopa-induced dyskinesia (LID). The aim of this study is to investigate the 
association between seven COMT gene single-nucleotide polymorphisms (SNPs) and the development of LID 
in patients with PD. Methods. 232 Caucasian patients with PD were investigated. 212 patients with PD 
received Levodopa therapy. Dyskinesia was assessed with the use of the Abnormal Involuntary Movement 
Scale (AIMS).  Genotyping was carried out on seven SNPs of the COMT gene (rs4680, rs6269, rs4633, rs4818, 
rs769224, rs165774, rs174696) using a real-time PCR method, and blind to the clinical status of the subjects. 
Results. We found association between four SNPs, rs165774, rs4818, rs4633, rs4680, and LID. When the 
duration of disease was added as a covariate in regression analysis, however, the results did not reach statistical 
significance. Only the additive model for rs165774 was found to be close to be statistical significance (OR = 
1.627 [0.976–2.741], permutation p = 0.057). Conclusions. The results failed to clearly support a contribution 
of the studied polymorphisms; this may be related to a dominant relationship with the disease duration 




Over 55 years after the discovery of its beneficial 
effects,1,2  Levodopa remains the mainstay of 
treatment for Parkinson’s disease (PD). The use of 
Levodopa for the treatment of motor symptoms at all 
stages of PD is supported by strong evidence.3 Long-
term treatment with Levodopa for PD, however, is 
frequently complicated by motor fluctuations and 
dyskinesias.3-6 Monotherapy with dopamine agonists 
in the early phases of the disease does reduce the risk 
for dyskinesias compared with the use of Levodopa, 
but dopamine agonists are unable to prevent 
dyskinesias once Levodopa is added, and which is 
always required once disease severity progresses.7 
Chronic Levodopa treatment has been reported to 
result in LID in up to 45% of Levodopa users within 
five  years.8 Clinical heterogeneity of LID suggests a 
significant role of endogenous factors in determining 
their prevalence, although  no effective drug 
treatment of levodopa-induced dyskinesia (LID) has 





attempted to  explain  the pathophysiology  of   this     
treatment  complication with an ultimate goal to 
develop such treatments9-11, but the exact 
pathological mechanism has also not yet been 
elucidated. Recently, Ivanova and Loonen developed 
the hypothesis that LID is related to an increased 
vulnerability to excitotoxicity of indirect pathway 
striatal medium spiny neurons potentiated due to the 
contribution of increased intracellular oxidative 
stress.12 This last phenomenon  is  expected to be  
caused  by the same genetic composition which 
causes the degeneration of dopaminergic 
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Dopamine can be considered to be a particularly 
neurotoxic endogenous substance: dopamine 
metabolism results in the release of hydrogen 
peroxide, which, in turn results in the production  of  
free  radicals,  which  then  cause cell damage.13 This 
damage is limited by the influence  of  certain  
enzymes  such  as  manganese superoxidedismutase 
(MnSOD), which scavenge these free radicals.14 This 
neurotoxicity is expected to be potentiated by 
biological factors which increase the intracellular 
levels of dopamine.  
Catechol-O-methyltransferase (COMT; EC 
2.1.1.6) is one of the most important enzymes in 
levodopa metabolism. It was identified by Julius 
Axelrod at the National Institute of Mental Health 
(USA) in the second half of the 1950s.15,16 COMT 
catalyzes methyl group transfer from S-adenosyl-L-
methionine to one of the hydroxyl groups of catechol 
in the presence of Mg2+ ions. COMT substrates 
include a wide variety of catechols (catecholamines, 
their hydroxylated metabolites, catecholestrogens, 
ascorbic acid, dietary phytochemicals, and medicinal 
compounds).15,16 The major physiological role of 
COMT is the elimination of biologically active or 
toxic catechols. Of special importance is the 
methylation of Levodopa to 3-O-methyldopa in 
Levodopa/aromatic amino acid decarboxylase 
inhibitor-treated Parkinson’s disease (PD) patients, 
because this metabolism markedly limits the 
availability of Levodopa to the brain.15 It has also 
been suggested that COMT plays a relevant role in 
modulating prefrontal dopamine 
neurotransmission.17 Polymorphic variants of the 
COMT gene determine the activity level of this 
enzyme.17-19 COMT exists in two forms: the soluble 
form (S-COMT) which is located in cytosol, and the 
membrane-bound form (MB-COMT) which is 
anchored to the rough endoplasmic reticulum. The 
two forms differ only by a 50 residue long extension 
in the MB-form, which is the signal sequence for 
membrane anchoring.20,21 In humans, the COMT 
gene is located on chromosome 22 band q11.21, and 
is composed of six exons.15 The first two exons are 
noncoding, while the translation initiation codons for 
the membrane bound and soluble isoforms are 
located on the third exon. Two separate promoters 
direct the synthesis of two partially overlapped 
transcripts: one of 1.5 kb that is constitutively 
expressed, and another of 1.3 kb which is subject to 
tissue-specific transcription regulation. The short 
transcript translates S-COMT and the longer 
transcript translates MB-COMT, and also the soluble 
form by the leaky scanning mechanism of 
translational initiation.15 The long transcript has been 
found in all tissues analyzed. The short transcript, on 
the other hand, is only found in very small amounts 
within the human brain. There is, however, no direct 
correlation between transcript and protein levels. In 
the human brain S-COMT represents about 30% of 
the total COMT.15  
Although several polymorphisms have been 
reported for the COMT gene, most of them appear 
not to have any physiological significance. However, 
the genetic variant Val158Met (rs4680) with low 
thermal stability and low COMT activity is a well-
established polymorphism that could contribute to 
various neuropsychiatric manifestations.18,19 Low 
COMT activity appears to have predominantly 
clinical effects within the prefrontal cortex (PFC) as 
in the PFC DA-transporters are expressed in low 
abundance within synapses, contrary to, for example, 
the striatum.19,22 Furthermore, the nonsynonymous 
Ala72Ser (rs6267) polymorphism has been 
associated with reduced COMT enzyme activity  and 
with a risk for schizophrenia23 Apart from the above 
mentioned Val158Met (rs4680), three single-
nucleotide polymorphisms (SNPs) were found: one 
in the S-COMT promoter region (rs6296) and two in 
the S- and MB-COMT coding region (c.186C>T, 
p.62His (rs4633), c.408C>T, p.136Lys (rs4818), 
next to rs4680). These were associated with 
differences in pain sensitivity and the likelihood of 
developing a chronic musculoskeletal pain 
condition.24 It was shown that these haplotypes 
modulate protein expression by altering mRNA 
secondary structure, thus stressing the functional 
significance of synonymous variations and 
importance of haplotypes.18 Another relevant 
synonymous variation includes c.597G>A, p.199Pro 
(rs769224).18 Xu et al demonstrated an association of 
the G–G–G vs. A–G–G haplotype of rs4633, rs4818 
and rs769224 concerning response to non-SSRIs in 
major depressive disorder.25 Recently published 
results revealed that homozygosity for rs4633 (TT), 
rs4680 (AA) and of the two linked rs4633-rs4680 
(TT/AA) was significantly associated to Levodopa 
effects in PD patients, while no significant 
differences were observed in patients who carried 
individual rs6269 and rs4818, the two linked rs6269-
rs4818 and the four combined COMT SNPs.26 These 
last observations contrast to the findings in patients 
with Attention-Deficit/Hyperactivity Disorder 
(ADHD) (64% using medication for it) in who the c.-
98A>G (rs6269) was associated with the largest 
influence on the hyperactivity/impulsivity scores. In 





PD patients, any existing significant differences 
were found for individual SNPs (rs6269; rs4633; 
rs4818; and rs4680) in the allele and genotype 
frequencies between PD cases and controls, but their 
division into haplotypes with low, medium and high 
COMT activity revealed that the high activity 
haplotypes needed a significantly higher levodopa 
dosage.27 In their study, the COMT haplotype 
seemed to have little influence on the development 
of Levodopa-induced dyskinesias. Meloto et al 
identified a functional marker situated in the 39 
untranslated region of a newfound splice variant 
(c.615+739G>A; rs165774) which displays unique 
substrate specificity, exhibiting enzymatic activity 
with dopamine, but not with epinephrine.28 They 
established that the pain-protective A allele of 
rs165774 coincides with lower COMT activity due 
to increased dopaminergic tone. Associations of 
rs165774 were also found by Higashiyama et al in 
patients with schizophrenia vs. healthy controls and 
by Seib et al in older women with depression.29,30 
Ittiwut et al found an association between rs4680 and 
c.615+1354C>T (rs174696) in European American 
patients with cocaine-induced paranoia.31 
 
In our current study we have investigated a 
possible existence of an association between rs4680, 
rs6269, rs4633, rs4818, rs769224, rs165774, as well 
as rs174696 and levodopa-induced dyskinesia in 232 
Caucasian PD patients from the neurological 
department of the Siberian State University Hospital 
of Tomsk, Russian Federation. The rationale for our 
study was that these polymorphisms have been 
demonstrated to induce certain functional changes. It 
was hypothesized that at least some of the 
biochemical alterations causing these functional 
changes might also affect the intracellular dopamine 
concentration, which could result in changed 






The work described in this article was carried out in 
accordance with The Code of Ethics of the World 
Medical Association (Declaration of Helsinki 1975, 
revised in Fortaleza, Brazil, 2013) for experiments 
involving humans. Patients were recruited from the 
neurology department of the Siberian State Medical 
University Hospital in Tomsk, Russian Federation. 
Written informed consent was obtained from each 
patient after obtaining approval for the study 
(protocol N 3604 10.02.2014) from the Local 
Bioethics Committee of the Siberian State Medical 
University. None of the participants had a 
compromised capacity/ability to consent; therefore 
consent from the next-of-kin was not necessary, and 
was not recommended by the local ethics committee. 
The inclusion criteria were a clinical diagnosis of 
Parkinson’s disease according to ICD-10 (G-20) and 
also prior long-term use of Levodopa. Exclusion 
criteria were non-Caucasian physical appearance 
(e.g., Mongoloid, Buryats or Khakassians), relevant 
psychiatric symptoms or any organic brain disorders 
other than Parkinson’s disease. These patients had 
not been treated with dopamine antagonists 
(antipsychotic or antiemetic drugs, including 
clozapine) for at least three years. Patients were 
assessed for the presence or absence of dyskinesia 
during ‘on’-phase according to the abnormal 
involuntary movement scale (AIMS).32-34 The AIMS 
scores were transformed into a binary form of LID 
(presence or absence of dyskinesia) with Schooler 
and Kane's criteria.35 
 
DNA analysis 
DNA was isolated from the leukocytes in whole 
peripheral blood using the standard phenol-
chloroform micro method.36 Genotyping was carried 
out on the MassARRAY Analyzer 4 (Agena 
Bioscience) using the set SEQUENOM 
Consumables iPLEX Gold 384. DNA sample 
preparation for SEQUENOM MassARRAY 
Analyzer 4 includes several steps: a standard PCR 
reaction to obtain the amplification products, a 
shrimp alkaline phosphatase reaction to neutralize 
the unincorporated dNTPs in the amplification 
products, the PCR iPLEX Gold extension reaction, 
and then placing the samples on a special chip 
(SpectroCHIP array) using Nanodispenser RS1000 
prior to loading them into the analyser. Genotyping 
was carried out on 7 SNPs of COMT genes (rs4680, 
rs6269, rs4633, rs4818, rs769224, rs165774, 
rs174696), which were selected after reviewing the 
literature for possible relevance. 
 
Statistical analysis 
Statistical analyses were performed using SPSS 
software for Windows, release 17. The Mann–
Whitney test (MWT) was used to compare 
qualitative traits and χ2 test for categorical traits. The 
Hardy–Weinberg equilibrium (HWE) of genotypic 
frequencies was tested using the χ2 test. The χ2 test 
and the Fisher’s exact test, if necessary, were used 
for between-group comparisons of genotype or allele 
frequencies.   
The analysis of association between the 
SNPs and the phenotype was carried out using 
logistic regression with adjustment for covariates. 
Additive, dominant and recessive models were 
tested, and the optimum model has been chosen 





using Akaike Information Criterion (AIC). 
Experiment-wise permutations were used to address 
the multiple testing issue, hence Bonferroni 
correction was not applicable. Models with 
permutation p-value < 0.05 were considered 
statistically significant. Odds ratio (OR) and 95% 
confidence intervals were estimated to assess the 
strength of genetic effect. The following filters were 
applied to the SNPs: minor allele frequency, 5%; 
deviation from Hardy-Weinberg equilibrium, 




A total of 232 Caucasian patients with PD were 
included, consisting of 149 females and 83 males 
(age range from 40 to 86 years, average age 68.7±7.6 
years). These patients demonstrated typical PD 
demographics, with a mean age of onset of 59.0 ± 9.5 
years, and a mean disease duration of 9.8 ± 5.6 years. 
The distribution of genotypes of studied genes 
corresponds to the Hardy-Weinberg equilibrium 
(data not shown). According to the predefined 
criteria, 58 patients suffered from dyskinesia. We 
found that four out of seven tested SNPs passed the 
significance thresholds for association with LID. 
Since associations can in part be explained by the 
effects of additional factors, such as sex and age, we 
carried out a regression analysis using LID as the 
dependent variable, the genotypes as the fixed factor 
and sex and age as covariates. Using linear 
regression models, we found association between 
four SNPs, rs165774, rs4818, rs4633, and rs4680, 
and LID; the best model (according to AIC values) 
was additive for rs165774 and rs4818 and dominant 
for rs4633 and rs4680 (Table 1). In case of rs165774, 
the rare allele was associated with an increased risk 
of LID (OR = 1.75 [95% CI 1.14-2.72]), while in 
case of rs4818, rs4633 and rs4680, the rare allele or 
homozygote genotype for the rare allele were 
protective against LID (OR = 0.57 [0.34-0.92], 0.45 
[0.23-0.89] and 0.46 [0.23-0.91], respectively). 
However, when the duration of disease was added as 
a covariate in regression analysis, the results did not 
reach statistical significance. Only the additive 
model for rs165774 was found to be close to 
statistical significance (OR = 1.627 [0.976–2.741], 




We have failed in this study of 232 white patients 
with Parkinson’s Disease (PD) to establish a clear 
relationship between any of the seven 
polymorphisms of the COMT gene and the 
prevalence of Levodopa-induced dyskinesia (LID). 
The associations that were found lost their statistical 
significance after correcting for disease duration. 
This last observation may correspond with the 
previously described association between some 
COMT gene polymorphisms and the onset of disease 
in 143 patients with PD.26 Watanabe et al found a 
slightly higher prevalence of PD in 30/118 patients 
with homozygosity for the low-activity allele of 
Val158Met (rs4680),37 but these findings were not 
reproduced by Contin et al in 104 patients, and by 
Cheshire et al in 285 patients.38,39 We had observed 
previously a significant association with PD for the 
c.615+739G>A (rs165774), but not Val158Met 
(rs4680), polymorphism and PD of the same patient 
population vs. 127 healthy controls.40 De Lau et al 
described the existence of a prospectively assessed 
correlation between the A-allele of the COMT 
Val158Met polymorphism and an increased risk of 
developing dyskinesias in 219 patients with PD.41 A 
comprehensive meta-analysis in which a total of 363 
datasets were included, consisting 56,998 cases and 
74,668 healthy controls from case control studies, as 
well as 2,547 trios from family based studies, 
showed a definite relationship between several 
psychiatric disorders, including, for example, 
attention-deficiency hyperactivity disorder (ADHD) 
and panic disorder for Caucasian samples.42  
We conclude that the tested polymorphisms, and in 
theory at least the COMT Val158Met polymorphism 
as described above, may have an influence on the 
prevalence of LID in PD, but this influence is small, 
and in our study confounded by a possible increased 
likelihood for PD to manifest itself, thus causing an 
increased disease duration in our patient population. 
In previous studies, we have observed that in both 
tardive dyskinesia as well as in LID,14,36,43 limb-
truncal dyskinesia may have a genetic background 
other than orofacial dyskinesia. Unfortunately, the 
number of patients in this study with LID is 
relatively small (N = 58), and too many suffered 
from both orofacial and limb-truncal dyskinesia to 
make further statistical analysis feasible. 
The strengths of our study include  the 
relatively large number of patients (N = 232); the 
thorough assessment of the severity of dyskinesia by 
direct clinical assessment with AIMS; the 
application of Schooler and Kane’s criteria to 
conclude to the presence of LID, and the assessment 
of seven putatively relevant polymorphisms of the 
COMT gene after carefully reviewing previous 
findings. The weaker points are the relatively low 
number of patients suffering from LID (N = 58, 
25%), and the co-occurrence of limb-truncal and 
orofacial dyskinesia in many of them. 
 




Table 1. SNPs associated with levodopa-induced dyskinesia 
SNP Best model OR [95% CI] Permutation p-value 
rs165774 Additive 1.75 [1.14-2.72] 0.011 
rs4818 Additive 0.57 [0.34-0.92] 0.025 
rs4633 Dominant 0.45 [0.23-0.89] 0.027 
rs4680 Dominant 0.46 [0.23-0.91] 0.025 
 
The results of this study illustrate that 
genetic variations of the activity of the COMT 
enzyme have only a modest influence on the clinical 
presentation of PD, and its treatment complications 
such as LID. The vulnerability in PD apparently 
differs from that in other neuropsychiatric disorders, 
such as ADHD.42 It can been suggested that this may 
be related to low expression of DA-transporters 
within the prefrontal cortex and not within synapses, 
contrary to, for example, the striatum.19,22 It is 
possible that  the abundance of DA-transporters 
within the striatum limits the influence of variations 
in COMT activity, because after re-uptake within 
dopaminergic terminals dopamine is generally 
processed differently (e.g., through mitochondrial 
monoamine oxidase). Moreover, the highly adaptive 
capacity of the functional nigrostriatal 
extrapyramidal connectivity may limit the influence 
of genetic variations in enzyme activity. This 
influence on the activity of the cortico-striato-
thalamo-cortical circuitry may be less than that 
within the prefrontal cortex or corticoid amygdala, 
which may play a role in causing other 
neuropsychiatric disorders.12 However, other PD 
manifestations, including cognitive symptoms, may 
be more dependent on the functioning of the 
prefrontal cortex. Recently, Zhang et al have 
demonstrated that COMT Val158Met polymorphism 
is probably not associated with increased risk of PD, 
but has an effect on the prefrontal executive function 
interacting with gender and dopaminergic 
medication.44 Specifically addressing manifestations 
related to dysfunction of the PFC (vigilance), 
corticoid amygdala (delusions) and hippocampal 
complex (hallucinations) may, in future, be more 





The possible association between seven putatively 
relevant genetic variants of COMT gene and 
prevalence of LID in 232 Caucasian patients with PD 
was studied. Although the association of four 
polymorphisms reached statistical significance, the 
relationship was masked after discounting the time 
frame of the proportion of patients in the sample 
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